Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Taláb, R."'
Autor:
Taláb R, Martin Vališ, Martin Bojar, Martin Vyhnalek, D. Škoda, Jiří Masopust, L. Glossová, Jakub Hort, Pavel Štourač, Waberzinek G
Publikováno v:
Der Nervenarzt. 79:891-898
Die Creutzfeldt-Jacob-Krankheit (CJK) ist eine extrem seltene Erkrankung des Zentralnervensystems, welche durch eine rasch-progrediente Demenz mit fatalem Ausgang gekennzeichnet ist. Die Diagnose beruht neben der Kenntnis des klinischen Erscheinungsb
Autor:
Hartung, Hp, Strasser Fuchs, S, Berger, T, Vass, K, Sindic, C, Dubois, B, Dive, D, Debruyne, J, Metz, L, Rice, G, Duquette, P, Lapierre, Y, Freedman, M, Traboulsee, A, O'Connor, P, Stourac, P, Taláb, R, Zapletalová, O, Kováøová, I, Medová, E, Fiedler, J, Frederiksen, J, Brochet, B, Moreau, T, Vermersch, P, Pelletier, J, Edan, G, Clanet, M, Clavelou, P, Lebrun Frenay, C, Gout, O, Kallela, M, Pirttilä, T, Ruutiainen, J, Koivisto, K, Reunanen, M, Elovaara, I, Villringer, A, Altenkirch, H, Wessel, K, Steinke, W, Kölmel, H, Oschmann, P, Diem, R, Dressel, A, Hoffmann, F, Baum, K, Jung, S, Petereit, Hf, Reske, D, Sailer, M, Köhler, J, Sommer, N, Hohlfeld, R, Henn, Kh, Steinbrecher, A, Tumani, H, Gold, R, Rieckmann, P, Komoly, R, Gács, G, Jakab, G, Csiba, L, Vécsei, L, Miller, A, Karussis, D, Chapman, J, Ghezzi, A, Comi, G, Gallo, Paolo, Cosi, V, Durelli, L, Anten, B, Visser, L, Myhr, Km, Szczudlik, A, Selmaj, K, Stelmasiak, Z, Podemski, R, Maciejek, Z, Cunha, L, Sega Jazbec, S, Montalba, X, Arbizu, T, Saiz, A, Bárcena, J, Arroyo, R, Fernández, O, Izquierdo, G, Casanova, B, Lycke, J, Kappos, L, Mattle, H, Beer, K, Coleman, R, Chataway, J, O'Riordan, J, Howell, S. .
Publikováno v:
Neurology, 77(9), 835-843. Lippincott Williams and Wilkins
Hartung, H P, Freedman, M S, Polman, C H, Edan, G, Kappos, L, Miller, D H, Montalban, X, Barkhof, F, Petkau, J, White, R, Sahajpal, V, Knappertz, V, Beckmann, K, Lanius, V, Sandbrink, R & Pohl, C 2011, ' Interferon beta-1b-neutralizing antibodies 5 years after clinically isolated syndrome ', Neurology, vol. 77, no. 9, pp. 835-843 . https://doi.org/10.1212/WNL.0b013e31822c90d7
Neurology, Vol. 77, no.9, p. 835-43 (2011)
Hartung, H P, Freedman, M S, Polman, C H, Edan, G, Kappos, L, Miller, D H, Montalban, X, Barkhof, F, Petkau, J, White, R, Sahajpal, V, Knappertz, V, Beckmann, K, Lanius, V, Sandbrink, R & Pohl, C 2011, ' Interferon beta-1b-neutralizing antibodies 5 years after clinically isolated syndrome ', Neurology, vol. 77, no. 9, pp. 835-843 . https://doi.org/10.1212/WNL.0b013e31822c90d7
Neurology, Vol. 77, no.9, p. 835-43 (2011)
To determine the frequency and consequences of neutralizing antibodies (NAbs) in patients with a first event suggestive of multiple sclerosis (MS) treated with interferon β-1b (IFNβ-1b).In the Betaseron/Betaferon in Newly Emerging MS For Initial Tr
Autor:
Strasser Fuchs, S, Berger, T, Vass, K, Sindic, C, Dubois, B, Dive, D, Debruyne, J, Metz, L, Rice, G, Duquette, P, Lapierre, Y, Freedman, M, Traboulsee, A, O'Connor, P, Stourac, P, Taláb, R, Zapletalová, O, Kovárová, I, Medová, E, Fiedler, J, Frederiksen, J, Brochet, B, Moreau, T, Vermersch, P, Pelletier, J, Edan, G, Clanet, M, Clavelou, P, Lebrun Frenay, C, Gout, O, Kallela, M, Pirttilä, T, Ruutiainen, J, Koivisto, K, Reunanen, M, Elovaara, I, Villringer, A, Altenkirch, H, Wessel, K, Hartung, Hp, Steinke, W, Kölmel, H, Oschmann, P, Diem, R, Dressel, A, Hoff, F, Baum, K, Jung, S, Felicitas Petereit, H, Reske, D, Sailer, M, Köhler, J, Sommer, N, Hohlfeld, R, Henn, Kh, Steinbrecher, A, Tumani, H, Gold, R, Rieckmann, P, Komoly, R, Gács, G, Jakab, G, Csiba, L, Vécsei, L, Miller, A, Karussis, D, Chapman, J, Ghezzi, A, Comi, G, Gallo, Paolo, Cosi, V, Durelli, L, Anten, B, Visser, L, Myhr, Km, Szczudlik, A, Selmaj, K, Stelmasiak, Z, Podemski, R, Maciejek, Z, Cunha, L, Sega Jazbec, S, Montalbán, X, Arbizu, T, Saiz, A, Bárcena, J, Arroyo, R, Fernández, O, Izquierdo, G, Casanova, B, Lycke, J, Kappos, L, Mattle, H, Beer, K, Coleman, R, Chataway, J, O'Riordan, J, Howell, S, Miller, Dh, Polman, Ch, Bauer, L, Ghazi, M, Pohl, C, Sandbrink, R, Barkhof, F, Uitdehaag, B, de Vera, A, Wu, S, Radü, Ew, Mcfarland, Hf, Kesselring, J, Petkau, Aj, Toyka, K. V.
Publikováno v:
Lancet Neurology, 8(11), 987-997. Lancet Publishing Group
Kappos, L, Freedman, M S, Polman, C H, Edan, G, Hartung, H P, Miller, D, Montalban, X, Barkhof, F, Radu, E W, Metzig, C, Bauer, L, Lanius, V, Sandbrink, R & Pohl, C 2009, ' Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial ', Lancet Neurology, vol. 8, no. 11, pp. 987-997 . https://doi.org/10.1016/S1474-4422(09)70237-6
The Lancet Neurology, Vol. 8, no.11, p. 987-97 (2009)
Kappos, L, Freedman, M S, Polman, C H, Edan, G, Hartung, H P, Miller, D, Montalban, X, Barkhof, F, Radu, E W, Metzig, C, Bauer, L, Lanius, V, Sandbrink, R & Pohl, C 2009, ' Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial ', Lancet Neurology, vol. 8, no. 11, pp. 987-997 . https://doi.org/10.1016/S1474-4422(09)70237-6
The Lancet Neurology, Vol. 8, no.11, p. 987-97 (2009)
BACKGROUND: The Betaferon/Betaseron in newly emerging multiple sclerosis for initial treatment (BENEFIT) trial investigated the effect of treatment with interferon beta-1b after a clinically isolated syndrome. The 5-year active treatment extension co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32de5c13d4271bf7c0708befa9bfb69e
https://lirias.kuleuven.be/handle/123456789/257768
https://lirias.kuleuven.be/handle/123456789/257768